MINNEAPOLIS – Jan. 2018
Be The Match BioTherapies®, an organization offering solutions for delivering cellular therapies, today announced that it has invested in Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy.
The investment was announced today as part of Tmunity’s Series A financing. Be The Match BioTherapies was joined in the investment round by Ping An Ventures, Parker Institute for Cancer Immunotherapy and Gilead Sciences.
“We are excited to support the mission of Tmunity Therapeutics, a promising early stage company that is working to build on the inspiring momentum of the field in creating personalized next-generation immunotherapies for cancer and other diseases,” said Amy Ronneberg, president of Be The Match BioTherapies. “The pace of discovery in cell therapy is accelerating rapidly, and the potential impact is expanding from blood cancers into a wide range of therapeutic settings. We are working alongside other industry leaders to help shape the future direction of the field and bring life-changing innovation to patients.”
“We are thrilled to have the support of Be The Match BioTherapies, which shares our belief in the vast untapped potential of T cell immunotherapies for patients,” said Usman “Oz” Azam, MD, president and chief executive officer of Tmunity. “As we work to create the next-generation of personalized therapies for cancer and other diseases, the support and expertise of Be The Match BioTherapies will be an important resource for us to draw on in support of our mission.”
Tmunity Therapeutics represents the second investment made by Be The Match BioTherapies since its creation by the National Marrow Donor Program® (NMDP)/Be The Match® in January, 2016. As one part of its patient-centered mission, Be The Match BioTherapies invests in companies it believes will have a significant impact on the science and clinical translation of cell therapy, at a stage of development where its support and core expertise enable the technology to reach patients faster.
About Be The Match BioTherapies
Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development—from discovery through commercialization. Built on the foundation established over the last 30 years by the NMDP/Be The Match, the organization has unparalleled experience managing cellular therapies. Its cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a robust, customizable technology platform. By leveraging its deep experience in cell sourcing and collection, Be The Match BioTherapies provides cells consented for research, clinical or commercial use as well as clinical trials services through its research program, the CIBMTR® (Center for International Blood and Marrow Transplant Research®). In addition, Be The Match BioTherapies has the infrastructure in place to collect patient outcomes at the time points required by regulatory authorities. For more information, please visit www.BeTheMatchBioTherapies.com.
About Tmunity Therapeutics
Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating broad collaborations with the University of Pennsylvania and the University of Minnesota with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. These personalized next-generation immunotherapies for cancer, infectious disease and autoimmune disease are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies. For more information, visit www.tmunity.com.